Safety and immunogenicity of trivalent inactivated influenza vaccine in adults 60 years of age and older: a phase II, a randomized, comparative trial in Kazakhstan.

Gulbanu SarsenbayevaTimur IssagulovMarkhabat KassenovRuslan AbitayMukhit OrynbayevMarina StukovaMaria PisarevaTimur DavlyatshinKutumbetov LespekBerik Khairullin

Published in: Human vaccines & immunotherapeutics (2020)

Comparison vaccines RIBSP and VAXIGRIP®, showed similar immunogenic activity. The RIBSP vaccine is safe and immunogenic for the elderly and conforms to international criteria in CPMP/BWP/214/96.

Keyphrases

phase ii
community dwelling
clinical trial
middle aged
open label
phase iii
placebo controlled
double blind
physical activity
randomized controlled trial
clinical evaluation